Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker Sells 100,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Monday, July 21st. The stock was sold at an average price of $11.52, for a total transaction of $1,152,000.00. Following the sale, the chief executive officer owned 1,462,223 shares in the company, valued at $16,844,808.96. This represents a 6.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Friday, June 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.45, for a total transaction of $1,145,000.00.
• On Tuesday, June 3rd, Eric Venker sold 566,278 shares of Roivant Sciences stock. The stock was sold at an average price of $11.22, for a total transaction of $6,353,639.16.
• On Monday, June 2nd, Eric Venker sold 433,722 shares of Roivant Sciences stock. The stock was sold at an average price of $11.07, for a total transaction of $4,801,302.54.
• On Tuesday, May 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.95, for a total transaction of $1,095,000.00.

Roivant Sciences Stock Up 1.5%

ROIV stock traded up $0.17 during trading on Friday, reaching $11.55. 4,358,236 shares of the company were exchanged, compared to its average volume of 6,275,449. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06. The stock's 50 day moving average price is $11.21 and its 200 day moving average price is $10.84.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). The company had revenue of $7.57 million for the quarter, compared to analysts' expectations of $62.17 million. Roivant Sciences had a negative return on equity of 14.76% and a negative net margin of 225.71%. During the same period in the prior year, the firm posted ($0.23) EPS. On average, research analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, June 18th. The Goldman Sachs Group raised shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 target price on the stock in a report on Thursday, July 10th.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently added to or reduced their stakes in ROIV. Parallel Advisors LLC boosted its holdings in Roivant Sciences by 80.5% during the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock worth $25,000 after buying an additional 1,108 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after buying an additional 1,948 shares in the last quarter. CWM LLC boosted its holdings in Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company's stock worth $34,000 after buying an additional 920 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Roivant Sciences during the fourth quarter worth about $39,000. Finally, UMB Bank n.a. raised its position in Roivant Sciences by 112.7% during the first quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after acquiring an additional 2,195 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.